EQL PHARMA AB
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.
EQL PHARMA AB (7JK) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, EQL PHARMA AB (7JK) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
EQL PHARMA AB - Net Assets Trend (None–None)
This chart illustrates how EQL PHARMA AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for EQL PHARMA AB (None–None)
The table below shows the annual net assets of EQL PHARMA AB from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to EQL PHARMA AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
EQL PHARMA AB Competitors by Market Cap
The table below lists competitors of EQL PHARMA AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SANOK RUBBER CO. ZY 02
F:1NX
|
$113.07 Million |
|
TIANYUN INTL. HLDG. LTD
F:5Q3
|
$113.08 Million |
|
Smart Sand Inc
NASDAQ:SND
|
$113.11 Million |
|
Prakash Industries Limited
NSE:PRAKASH
|
$113.14 Million |
|
Jinmao Property Services Co. Limited
PINK:JPPSF
|
$113.01 Million |
|
Fossil Group Inc
NASDAQ:FOSL
|
$112.95 Million |
|
Samyang Cor
KO:145990
|
$112.94 Million |
|
Kolon Plastics
KO:138490
|
$112.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in EQL PHARMA AB's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares EQL PHARMA AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently EQL PHARMA AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares EQL PHARMA AB's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| EQL PHARMA AB (7JK) | €- | N/A | N/A | $113.05 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |